Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 833
  • Shares Outstanding, K 61,719
  • Annual Sales, $ 5,330 K
  • Annual Income, $ -72,530 K
  • 60-Month Beta -0.90
  • Price/Sales 11.61
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ATHX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.03
  • Most Recent Earnings $-0.15 on 11/16/23
  • Latest Earnings Date 11/20/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0116 +16.38%
on 01/08/24
0.0278 -51.44%
on 12/11/23
-0.0106 (-43.98%)
since 12/08/23
3-Month
0.0116 +16.38%
on 01/08/24
0.3290 -95.90%
on 10/09/23
-0.2887 (-95.53%)
since 10/06/23
52-Week
0.0116 +16.38%
on 01/08/24
1.9900 -99.32%
on 02/07/23
-0.9465 (-98.59%)
since 01/06/23

Most Recent Stories

More News
Athersys to Participate in Three Upcoming Conferences

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences...

ATHX : 0.0135 (-33.50%)
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics...

ATHX : 0.0135 (-33.50%)
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society...

ATHX : 0.0135 (-33.50%)
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents...

ATHX : 0.0135 (-33.50%)
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common...

ATHX : 0.0135 (-33.50%)
Athersys to Host Business Update Conference Call on April 20th

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference...

ATHX : 0.0135 (-33.50%)
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.

ATHX : 0.0135 (-33.50%)
Athersys Announces Successful Type B Meeting with the FDA

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced planned amendments to its MASTERS-2 clinical...

ATHX : 0.0135 (-33.50%)
Athersys Expands IP Protection with First New Patent for SIFU® Technology

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the United States Patent...

ATHX : 0.0135 (-33.50%)
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® ( invimestrocel ) for critical care indications, announced today that the Company has been granted...

ATHX : 0.0135 (-33.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0289
2nd Resistance Point 0.0250
1st Resistance Point 0.0193
Last Price 0.0135
1st Support Level 0.0097
2nd Support Level 0.0058
3rd Support Level 0.0001

See More

52-Week High 1.9900
Fibonacci 61.8% 1.2343
Fibonacci 50% 1.0008
Fibonacci 38.2% 0.7673
Last Price 0.0135
52-Week Low 0.0116

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar